FOCUS On Kinase Inhibitors. The FDA recently approved its 100th kinase inhibitor, marking a major milestone in precision medicine since its first kinase inhibitor approval (Imatinib)
FOCUS on Alzheimer’s disease. A recent paper by AA Pieper and colleagues demonstrated that pharmacologic restoration of NAD+ homeostasis with P7C3-A20 reverses cognitive deficits and neuropathology
FOCUS on Drug Failures. On December 22nd AstraZeneca reported on the LATIFY Phase III trial of ATR inhibitor ceralasertib (AZD6738) in combination with Imfinzi (Durvalumab), which
FOCUS on Clinical Trials. Takeda has announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib
FOCUS on Drug Approvals. On December 17th the FDA granted regular approval to PARP inhibitor drug Rubraca (Rucaparib, pharmaand GmbH), for treatment of adults with a
FOCUS on Drug Failures. Yesterday Sanofi provided an update on tolebrutinib (SAR442168, a Bruton tyrosine kinase inhibitor), in primary progressive multiple sclerosis. Results from the PERSEUS
BOGO
